CVE-2006-5374 in Pharmaceutical
Summary
by MITRE
Unspecified vulnerability in Oracle Pharmaceutical Applications 4.5.1 has unknown impact and remote authenticated attack vectors, aka Vuln# PHAR01.
Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
Analysis
by VulDB Data Team • 04/24/2026
The vulnerability identified as CVE-2006-5374 affects Oracle Pharmaceutical Applications version 4.5.1, representing a security weakness within the pharmaceutical industry's specialized software ecosystem. This unspecified vulnerability falls under the broader category of application-level security flaws that can potentially compromise sensitive healthcare data and pharmaceutical operations. The vulnerability is particularly concerning because it allows for remote authenticated attack vectors, meaning that an attacker with valid credentials could exploit this weakness from a remote location. This characteristic significantly broadens the attack surface and increases the potential impact on pharmaceutical organizations that rely heavily on secure data handling and regulatory compliance.
The technical nature of this vulnerability remains unspecified in the initial description, which is common with older CVE entries that were documented before comprehensive vulnerability classification standards were fully established. However, given that this affects a pharmaceutical application and allows remote authenticated access, the flaw likely resides in authentication mechanisms, input validation, or session management components. The vulnerability's classification as "unspecified" suggests it may involve multiple potential attack vectors or that the specific technical details were not fully documented at the time of reporting. This lack of specificity often indicates that the vulnerability could manifest in various forms including but not limited to buffer overflows, injection flaws, or authentication bypass mechanisms that are particularly dangerous in healthcare environments where data integrity and patient privacy are paramount.
The operational impact of this vulnerability extends beyond simple data compromise, particularly within the pharmaceutical industry where applications handle sensitive patient information, drug development data, clinical trial results, and regulatory compliance documentation. Organizations using Oracle Pharmaceutical Applications 4.5.1 face potential exposure to unauthorized access to proprietary research data, patient medical records, and business-critical pharmaceutical information. The remote authenticated attack vector means that attackers could potentially gain access from anywhere in the world, making traditional network perimeter defenses insufficient for protection. This vulnerability could enable attackers to manipulate pharmaceutical data, disrupt clinical research processes, or access confidential business information that could affect competitive positioning and regulatory compliance. The pharmaceutical sector's stringent regulatory requirements under frameworks like HIPAA and FDA regulations make such vulnerabilities particularly dangerous as they could result in significant legal and financial consequences.
Mitigation strategies for this vulnerability should focus on immediate patching and remediation efforts, although the unspecified nature of the flaw may require organizations to implement comprehensive security monitoring and assessment procedures. Organizations should conduct thorough vulnerability assessments to identify potential related weaknesses in their network infrastructure and application environments. Given that this vulnerability affects a specific version of Oracle Pharmaceutical Applications, upgrading to a patched version represents the most direct mitigation approach. However, organizations should also implement additional security controls such as network segmentation, enhanced monitoring of authentication activities, and regular security assessments of their pharmaceutical applications. The vulnerability's classification as remote authenticated suggests that implementing robust access controls, multi-factor authentication, and continuous monitoring of user activities could help reduce the risk of exploitation. Organizations should also consider the broader implications of this vulnerability within their compliance frameworks and ensure that any security measures implemented align with industry standards and regulatory requirements for healthcare information systems. This vulnerability highlights the critical importance of maintaining current security patches and implementing comprehensive security monitoring for specialized industry applications that handle sensitive data.